Natural evolution of TEM-1 β-lactamase: Experimental reconstruction and clinical relevance

FEMS Microbiology Reviews

Volumn 34, Issue 6, 2010, Pages 1015-1036

  Salverda, Merijn L M ^a   de Visser, J Arjan G M ^a   Barlow, Miriam ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Directed evolution; Evolution of antibiotic resistance; Predicting antibiotic resistance; Structure function relationship; TEM lactamase

Indexed keywords

AMINO ACID; AMOXICILLIN; AMPICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAM INHIBITOR; BETA LACTAMASE CTX M; BETA LACTAMASE INHIBITOR; BETA LACTAMASE TEM 1; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN; CEPHALOSPORIN C; CLAVULANIC ACID; PENICILLIN G; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME STABILITY; ENZYME SYNTHESIS; GENE FREQUENCY; HYDROGEN BOND; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; EVOLUTION, MOLECULAR; HUMANS; MOLECULAR CONFORMATION; MUTATION;

EID: 78649360645     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1111/j.1574-6976.2010.00222.x     Document Type: Review

References (125)

1. Ambler RP, Coulson AFW, Frere JM, Ghusen JM, Joris B, Forsman M, Levesque RC, Tiraby G & Waley SG (1991) A standard numbering scheme for the class A β-lactamases. Biochem J 276: 269-272.
2. Arlet G, Rouveau M, Fournier G, Lagrange PH & Philippon A (1993) Novel, plasmid-encoded, TEM-derived extendedspectrum β-lactamase in Klebsiella pneumoniae conferring higher resistance to aztreonam than to extended-spectrum cephalosporins. Antimicrob Agents Ch 37: 2020-2023.
3. Arpin C, Quentin C, Grobost F, Cambau E, Robert J, Dubois V, Coulange L & Andre C & Scientific Committee ONERBA (2009) Nationwide survey of extended-spectrum β-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemoth 63: 1205-1214.
4. Baldwin AJ, Busse K, Simm AM & Jones DD (2008) Expanded molecular diversity generation during directed evolution by trinucleotide exchange (TriNEx). Nucleic Acids Res 36: e77.
5. Barlow M & Hall BG (2002) Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the TEM β-lactamase. Genetics 160: 823-832.
6. Barlow M & Hall BG (2003a) Experimental prediction of the evolution of cefepime resistance from the CMY-2 AmpC β-lactamase. Genetics 164: 23-29.
7. Barlow M & Hall BG (2003b) Experimental prediction of the natural evolution of antibiotic resistance. Genetics 163: 1237-1241.
8. Barlow M, Fatollahi J & Salverda M (2009) Evidence for recombination among the alleles encoding TEM and SHV β-lactamases. J Antimicrob Chemoth 63: 256-259.
9. Bershtein S & Tawfik DS (2008) Ohno's model revisited: measuring the frequency of potentially adaptive mutations under various mutational drifts. Mol Biol Evol 25: 2311-2318.
10. Bershtein S, Goldin K & Tawfik DS (2008) Intense neutral drifts yield robust and evolvable consensus proteins. J Mol Biol 379: 1029-1044.
11. Blazquez J, Morosini MI, Negri MC, Gonzalezleiza M & Baquero F (1995) Single amino-acid replacements at positions altered in naturally-occurring extended-spectrum TEM β-lactamases. Antimicrob Agents Ch 39: 145-149.
12. Blazquez J, Negri MC, Morosini MI, Gomez-Gomez JM & Baquero F (1998) A237T as a modulating mutation in naturally occurring extended-spectrum TEM-type β-lactamases. Antimicrob Agents Ch 42: 1042-1044.
13. Blazquez J,Morosini MI, Negri MC & Baquero F (2000) Selection of naturally occurring extended-spectrum TEM β-lactamase variants by fluctuating β-lactam pressure. Antimicrob Agents Ch 44: 2182-2184.
14. Bloom JD, Silberg JJ, Wilke CO, Drummond DA, Adami C & Arnold FH (2005) Thermodynamic prediction of protein neutrality. P Natl Acad Sci USA 102: 606-611.
15. Bradford PA & Sanders CC (1995) Development of test panel of β-lactamases expressed in a common Escherichia coli host background for evaluation of new β-lactam antibiotics. Antimicrob Agents Ch 39: 308-313.
16. Brasme L, Nordmann P, Fidel F et al. (2007) Incidence of class A extended-spectrum β-lactamases in Champagne-Ardenne (France): a 1 year prospective study. J Antimicrob Chemoth 60: 956-964.
17. Bret L, Chaibi EB, Chanal-Claris C, Sirot D, Labia R & Sirot J (1997) Inhibitor-resistant TEM (IRT) β-lactamases with different substitutions at position 244. Antimicrob Agents Ch 41: 2547-2549.
18. Camps M, Naukkarinen J, Johnson BP & Loeb LA (2003) Targeted gene evolution in Escherichia coli using a highly errorprone DNA polymerase I. P Natl Acad Sci USA 100: 9727-9732.
19. Canica MM, Caroff N, Barthelemy M, Labia R, Krishnamoorthy R, Paul G & Dupret JM (1998) Phenotypic study of resistance of β-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp(276). Antimicrob Agents Ch 42: 1323-1328.
20. Cantu C & Palzkill T (1998) The role of residue 238 of TEM-1 β-lactamase in the hydrolysis of extended-spectrum antibiotics. J Biol Chem 273: 26603-26609.
21. Cantu C, Huang WZ & Palzkill T (1996) Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 β-lactamase with altered substrate specificity for aztreonam and ceftazidime. J Biol Chem 271: 22538-22545.
22. Caporale B, Franceschini N, Perilli M, Segatore B, Rossolini GM & Amicosante G (2004) Biochemical characterization of laboratory mutants of extended-spectrum β-lactamase TEM-60. Antimicrob Agents Ch 48: 3579-3582.
23. Chaibi EB, Farzaneh S, Peduzzi J, BarthelemyM& Labia R (1996) An additional ionic bond suggested by molecular modelling of TEM-2 might induce a slight discrepancy between catalytic properties of TEM-1 and TEM-2 β-lactamases. FEMS Microbiol Lett 143: 121-125.
24. Chaibi EB, Peduzzi J, Farzaneh S, Barthelemy M, Sirot D & Labia R (1998) Clinical inhibitor-resistant mutants of the β-lactamase TEM-1 at amino-acid position 69: kinetic analysis and molecular modelling. BBA-Protein Struct M 1382: 38-46.
25. Chaibi EB, Sirot D, Paul G & Labia R (1999) Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemoth 43: 447-458.
26. Chouchani C, Berlemont R, Masmoudi A, Galleni M, Frere JM, Belhadj O & Ben-Mahrez K (2006) A novel extended-spectrum TEM-type β-lactamase, TEM-138, from Salmonella enterica serovar Infantis. Antimicrob Agents Ch 50: 3183-3185.
27. Datta N & Kontomichalou P (1965) Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 208: 239-241.
28. Datta N & Richmond MH (1966) Purification and properties of a penicillinase whose synthesis is mediated by an R-factor in Escherichia coli. Biochem J 98: 204-209.
29. Delaire M, Labia R, Samama JP & Masson JM (1992) Sitedirected mutagenesis at the active-site of Escherichia coli TEM-1 β-lactamase: suicide inhibitor-resistant mutants reveal the role of Arginine-244 and Methionine-69 in catalysis. J Biol Chem 267: 20600-20606.
30. DeLano WL (2002) The PyMOL molecular graphic system. DeLano Scientific, Palo Alto, CA.
31. Delmas J, Robin F, Bittar F, Chanal C & Bonnet R (2005) Unexpected enzyme TEM-126: role of mutation Asp179Glu. Antimicrob Agents Ch 49: 4280-4287.
32. DePristo MA, Weinreich DM & Hartl DL (2005) Missense meanderings in sequence space: a biophysical view of protein evolution. Nat Rev Genet 6: 678-687.
33. Driffield KL, Bostock JM, Miller K, O'Neill AJ, Hobbs JK & Chopra I (2006) Evolution of extended-spectrum β-lactamases in a MutS-deficient Pseudomonas aeruginosa hypermutator. J Antimicrob Chemoth 58: 905-907.
34. DuboisW, Poirel L, Arpin C, Coulange L, Bebear C, Nordmann P & Quentin C (2004) SHV-49, a novel inhibitor-resistant β-lactamase in a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Ch 48: 4466-4469.
35. Elwell LP, Roberts M, Mayer LW & Falkow S (1977) Plasmidmediated β-lactamase production in Neisseria gonorrhoeae. Antimicrob Agents Ch 11: 528-533.
36. Fang H, Ataker F, Hedin G & Dornbusch K (2008) Molecular epidemiology of extended-spectrum β-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 46: 707-712.
37. Farzaneh S, Chaibi EB, Peduzzi J, Barthelemy M, Labia R, Blazquez J & Baquero F (1996) Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) β-lactamase. Antimicrob Agents Ch 40: 2434-2436.
38. Fiett J, Palucha A, Miaczynska B, Stankiewicz M, Przondo-Mordarska H, Hryniewicz W & Gniadkowski M (2000) A novel complex mutant β-lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extendedspectrum β-lactamase-producing Klebsiellae. Antimicrob Agents Ch 44: 1499-1505.
39. Fisher J, Charnas RL & Knowles JR (1978) Kinetic studies on inactivation of Escherichia coli RTEM β-lactamase by clavulanic acid. Biochemistry 17: 2180-2184.
40. Fujii R, Kitaoka M & Hayashi K (2004) One-step random mutagenesis by error-prone rolling circle amplification. Nucleic Acids Res 32: e145.
41. Fujii R, KitaokaM& Hayashi K (2006) RAISE: a simple and novel method of generating random insertion and deletion mutations. Nucleic Acids Res 34: e30.
42. Giakkoupi P, Miriagou V, Gazouli M, Tzelepi E, Legakis NJ & Tzouvelekis LS (1998) Properties of mutant SHV-5 β-lactamases constructed by substitution of isoleucine or valine for methionine at position 69. Antimicrob Agents Ch 42: 1281-1283.
43. Giakkoupi P, Tzelepi E, Tassios PT, Legakis NJ & Tzouvelekis LS (2000) Detrimental effect of the combination of R164S with G238S in TEM-1 β-lactamase on the extended-spectrum activity conferred by each single mutation. J Antimicrob Chemoth 45: 101-104.
44. Gniadkowski M (2008) Evolution of extended-spectrum betalactamases by mutation. Clin Microbiol Infec 14: 11-32.
45. Goldsmith M & Tawfik S (2009) Potential role of phenotypic mutations in the evolution of protein expression and stability. P Natl Acad Sci USA 106: 6197-6202.
46. Hall A & Knowles JR (1976) Directed selective pressure on a β-lactamase to analyze molecular changes involved in development of enzyme function. Nature 264: 803-804.
47. Hall BG (2002) Predicting evolution by in vitro evolution requires determining evolutionary pathways. Antimicrob Agents Ch 46: 3035-3038.
48. Hecky J & Müller KM (2005) Structural perturbation and compensation by directed evolution at physiological temperature leads to thermostabilization of β-lactamase. Biochemistry 44: 12640-12654.
49. Hernandez JR, Martinez-Martinez L, Canton R, Coque TM & Pascual A & Spanish Group for Nosocomial Infections (GEIH) (2005) Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Antimicrob Agents Ch 49: 2122-2125.
50. Holloway AK, Palzkill T & Bull JJ (2007) Experimental evolution of gene duplicates in a bacterial plasmid model. J Mol Evol 64: 215-222.
51. Huang WZ & Palzkill T (1997) A natural polymorphism in β-lactamase is a global suppressor. P Natl Acad Sci USA 94: 8801-8806.
52. Huang WZ, Le QQ, Larocco M & Palzkill T (1994) Effect of Threonine-to-Methionine substitution at position 265 on structure and function of TEM-1 β-lactamase. Antimicrob Agents Ch 38: 2266-2269.
53. Imtiaz U, Billings E, Knox JR, Manavathu EK, Lerner SA & Mobashery S (1993) Inactivation of class-A β-lactamases by clavulanic acid: the role of Arginine-244 in a proposed nonconcerted sequence of events. J Am Chem Soc 115: 4435-4442.
54. Imtiaz U, Manavathu EK, Mobashery S & Lerner SA (1994) Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 β-lactamase as a result of a 2nd mutation (Arg to Ser at position 164) that enhances activity against ceftazidime. Antimicrob Agents Ch 38: 1134-1139.
55. Inouye S, Soberon X, Franceschini T, Nakamura K, Itakura K & Inouye M (1982) Role of positive charge on the aminoterminal region of the signal peptide in protein secretion across the membrane. P Natl Acad Sci USA 79: 3438-3441.
56. Jelsch C, Mourey L, Masson JM & Samama JP (1993) Crystalstructure of Escherichia coli TEM1 β-lactamase at 1.8 Angstrom resolution. Proteins 16: 364-383.
57. Kajava AV, Zolov SN, Kalinin AE & Nesmeyanova MA (2000) The net charge of the first 18 residues of the mature sequence affects protein translocation across the cytoplasmic membrane of gram-negative bacteria. J Bacteriol 182: 2163-2169.
58. Kather I, Jakob RP, Dobbek H & Schmid FX (2008) Increased folding stability of TEM-1 β-lactamase by in vitro selection. J Mol Biol 383: 238-251.
59. Kjerulf A, Hansen DS, Sandvang D, Hansen F & Frimodt-Moller N (2008) The prevalence of ESBL-producing E. coli and Klebsiella strains in the Copenhagen area of Denmark. APMIS 116: 118-124.
60. Knowles JR (1985) Penicillin resistance: the chemistry of β-lactamase inhibition. Accounts Chem Res 18: 97-104.
61. Knox JR (1995) Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity, and threedimensional structure. Antimicrob Agents Ch 39: 2593-2601.
62. Kopsidas G, Carman RK, Stutt EL, Raicevic A, Roberts AS, Siomos MA, Dobric N, Pontes-Braz L & Coia G (2007) RNA mutagenesis yields highly diverse mRNA libraries for in vitro protein evolution. BMC Biotechnol 7: 18.
63. Kuzin AP, Liu HS, Kelly JA & Knox JR (1995) Binding of cephalothin and cefotaxime to D-Ala-D-Ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum β-lactamases. Biochemistry 34: 9532-9540.
64. Labia R, Philippon A, Legoffic F & Faye JC (1975) Identification of β-lactamase R-TEM of Pseudomonas aeruginosa. Biochimie 57: 139-143.
65. Labia R, Morand A, Tiwari K, Sirot J, Sirot D & Petit A (1988) Interactions of new plasmid-mediated β-lactamases with 3rdgeneration cephalosporins. Rev Infect Dis 10: 885-891.
66. Lartigue MF, Leflon-Guibout W, Poirel L, Nordmann P & Nicolas-Chanoine MH (2002) Promoters P3, Pa/Pb, P4, and P5 upstream from bla(TEM) genes and their relationship to blactam resistance. Antimicrob Agents Ch 46: 4035-4037.
67. Livermore DM, Canton R, Gniadkowski M et al. (2007) CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemoth 59: 165-174.
68. Long-McGie J, Liu AD & Schellenberger V (2000) Rapid in vivo evolution of a β-lactamase using phagemids. Biotechnol Bioeng 68: 121-125.
69. Machado E, Coque TM, Canton R, Novais A, Sousa JC, Baquero F & Peixe L & Portuguese Resistance Study Group (2007) High diversity of extended-spectrum β-lactamases among clinical isolates of Enterobacteriaceae from Portugal. J Antimicrob Chemoth 60: 1370-1374.
70. Marciano DC, Pennington JM,Wang X,Wang J, Chen Y, Thomas VL, Shoichet BK & Palzkill T (2008) Genetic and structural characterization of an L201P global suppressor substitution in TEM-1 β-lactamase. J Mol Biol 384: 151-164.
71. Martinez JL, Baquero F & Andersson DI (2007) Predicting antibiotic resistance. Nat Rev Microbiol 5: 958-965.
72. Matagne A & Frere JM (1995) Contribution of mutant analysis to the understanding of enzyme catalysis: the case of class-A β-lactamases. BBA-Protein Struct M 1246: 109-127.
73. Matagne A, Lamotte-Brasseur J & Frere JM (1998) Catalytic properties of class A β-lactamases: efficiency and diversity. Biochem J 330: 581-598.
74. Matthew M (1979) Plasmid-mediated β-lactamases of gramnegative bacteria: properties and distribution. J Antimicrob Chemoth 5: 349-358.
75. Maveyraud L, Saves I, Burlet-Schiltz O, Swaren P, Masson JM, Delaire M, Mourey L, Prome JC & Samama JP (1996) Structural basis of extended spectrum TEM β-lactamases: crystallographic, kinetic, and mass spectrometric investigations of enzyme mutants. J Biol Chem 271: 10482-10489.
76. Medeiros AA (1997) Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 24: S19-S45.
77. Medeiros AA & Obrien TF (1975) Ampicillin resistant Haemophilus influenzae type B possessing a TEM-type β-lactamase but little permeability barrier to ampicillin. Lancet 1: 716-718.
78. Minasov G, Wang XJ & Shoichet BK (2002) An ultrahigh resolution structure of TEM-1 β-lactamase suggests a role for Glu166 as the general base in acylation. J Am Chem Soc 124: 5333-5340.
79. Mroczkowska JE & Barlow M (2008a) Fitness trade-offs in bla(TEM) evolution. Antimicrob Agents Ch 52: 2340-2345.
80. Mroczkowska JE & Barlow M (2008b) Recombination and selection can remove bla(TEM) alleles from bacterial populations. Antimicrob Agents Ch 52: 3408-3410.
81. Mulvey MR, Bryce E, Boyd D, Ofner-Agostini M, Christianson S, Simor AE & Paton S & Canadian Nosocomial Infection Surveillance Program (2004) Ambler class A extendedspectrum β-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob Agents Ch 48: 1204-1214.
82. Neuwirth C, Madec S, Siebor E, Pechinot A, Duez JM, Pruneaux M, Fouchereau-Peron M, Kazmierczak A & Labia R (2001) TEM-89 β-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3. Antimicrob Agents Ch 45: 3591-3594.
83. Novais A, Comas I, Baquero F, Canton R, Coque TM, Moya A, Gonzalez-Candelas F & Galan JC (2010) Evolutionary trajectories of β-lactamase CTX-M-1 cluster enzymes: predicting antibiotic resistance. Plos Pathogens 6: e1000735.
84. Orencia MC, Yoon JS, Ness JE, Stemmer WP & Stevens RC (2001) Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat Struct Biol 8: 238-242.
85. Osuna J, Perez-Blancas A & Soberon X (2002) Improving a circularly permuted TEM-1 β-lactamase by directed evolution. Protein Eng 15: 463-470.
86. Osuna J, Yanez J, Soberon X & Gaytan P (2004) Protein evolution by codon-based random deletions. Nucleic Acids Res 32: e136.
87. Page MGP (2008) Extended-spectrum β-lactamases: structure and kinetic mechanism. Clin Microbiol Infec 14: 63-74.
88. Park YJ, Park SY, Oh EJ, Park JJ, Lee KY, Woo GJ & Lee K (2005) Occurrence of extended-spectrum β-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn Micr Infec Dis 51: 265-269.
89. Perilli M, Segatore B, De Massis MR, Pagani L, Luzzaro F, Rossolini GM & Amicosante G (2002) Biochemical characterization of TEM-92 extended-spectrum β-lactamase, a protein differing from TEM-52 in the signal peptide. Antimicrob Agents Ch 46: 3981-3983.
90. Petit A, Maveyraud L, Lenfant F, Samama JP, Labia R & Masson JM (1995) Multiple substitutions at position 104 of β-lactamase TEM-1: assessing the role of this residue in substrate-specificity. Biochem J 305: 33-40.
91. Podbielski A, Schonling J, Melzer B, Warnatz K & Leusch HG. (1991) Molecular characterization of a new plasmid-encoded SHV-type β-lactamase (SHV-2 variant) conferring high-levelcefotaxime resistance upon Klebsiella pneumoniae. J Gen Microbiol 137: 569-578.
92. Prinarakis EE, Miriagou V, Tzelepi E, GazouliM& Tzouvelekis LS (1997) Emergence of an inhibitor-resistant β-lactamase (SHV-10) derived from an SHV-5 variant. Antimicrob Agents Ch 41: 838-840.
93. Raquet X, Lamottebrasseur J, Fonze E, Goussard S, Courvalin P & Frere JM (1994) TEM β-lactamase mutants hydrolyzing thirdgeneration cephalosporins. J Mol Biol 244: 625-639.
94. Raquet X, Vanhove M, Lamottebrasseur J, Goussard S, Courvalin P & Frere JM (1995) Stability of TEM β-lactamase mutants hydrolyzing 3rd-generation cephalosporins. Proteins 23: 63-72.
95. Robin F, Delmas J, Chanal C, Sirot D, Sirot J & Bonnet R (2005) TEM-109 (CMT-5), a natural complex mutant of TEM-1 β-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5). Antimicrob Agents Ch 49: 4443-4447.
96. Robin F, Delmas J, Archambaud M, Schweitzer C, Chanal C & Bonnet R (2006) CMT-type β-lactamase TEM-125, an emerging problem for extended-spectrum β-lactamase detection. Antimicrob Agents Ch 50: 2403-2408.
97. Robin F, Delmas J, Brebion A, Dubois D, Constantin JM & Bonnet R (2007a) TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum β-lactamases. Antimicrob Agents Ch 51: 4181-4183.
98. Robin F, Delmas J, Schweitzer C, Tournilhac O, Lesens O, Chanal C & Bonnet R (2007b) Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. Antimicrob Agents Ch 51: 1304-1309.
99. Robinson MK, Bennett PM & Richmond MH (1977) Inhibition of TnA translocation by TnA. J Bacteriol 129: 407-414.
100. Romero EDV, Padilla TP, Hernandez AH, Grande RP, Vazquez MF, Garcia IG, Garcia-Rodriguez JA & Bellido JLM (2007) Prevalence of clinical isolates of Escherichia coli and Klebsiella spp. producing multiple extended-spectrum β-lactamases. Diagn Micr Infec Dis 59: 433-437.
101. Rossolini GM, D'Andrea MM & Mugnaioli C (2008) The spread of CTX-M-type extended-spectrum β-lactamases. Clin Microbiol Infec 14: 33-41.
102. Saves I, Burletschiltz O, Maveyraud L, Samama JP, Prome JC & Masson JM (1995a) Mass-spectral kinetic study of acylation and deacylation during the hydrolysis of penicillins and cefotaxime by β-lactamase TEM-1 and the G238S mutant. Biochemistry 34: 11660-11667.
103. Saves I, Burletschiltz O, Swaren P, Lefevre F, Masson JM, Prome JC & Samama JP (1995b) The Asparagine to Aspartic-acid substitution at position-276 of TEM-35 and TEM-36 is involved in the β-lactamase resistance to clavulanic acid. J Biol Chem 270: 18240-18245.
104. Shahid M, Sobia E, Singh A, Malik A, Khan HM, Jonas D & Hawkey PM (2009) Beta-lactams and beta-lactamaseinhibitors in current- or potential-clinical practice: a comprehensive update. Crit Rev Microbiol 35: 81-108.
105. Sideraki V, Huang WZ, Palzkill T & Gilbert HF (2001) A secondary drug resistance mutation of TEM-1 β-lactamase that suppresses misfolding and aggregation. P Natl Acad Sci USA 98: 283-288.
106. Simm AM, Baldwin AJ, Busse K & Jones DD (2007) Investigating protein structural plasticity by surveying the consequence of an amino acid deletion from TEM-1 β-lactamase. FEBS Lett 581: 3904-3908.
107. Sommer MOA, Dantas G & Church GM (2009) Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 325: 1128-1131.
108. Sowek JA, Singer SB, Ohringer S, Malley MF, Dougherty TJ, Gougoutas JZ & Bush K (1991) Substitution of Lysine at position 104 or 240 of TEM-1ptz18r β-lactamase enhances the effect of Serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry 30: 3179-3188.
109. Stemmer WP (1994) Rapid evolution of a protein in vitro by DNA shuffling. Nature 370: 389-391.
110. Swaren P, Golemi D, Cabantous S, Bulychev A, Maveyraud L, Mobashery S & Samama JP (1999) X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 β-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid. Biochemistry 38: 9570-9576.
111. Sykes RB & Bush K (1982) The Chemistry and Biology of β-Lactam Antibiotics. Academic Press, New York.
112. Taibi-Tronche P, Massova I, Vakulenko SB, Lerner SA & Mobashery S (1996) Evidence for structural elasticity of class A β-lactamases in the course of catalytic turnover of the novel cephalosporin cefepime. J Am Chem Soc 118: 7441-7448.
113. Thomas VL, Golemi-Kotra D, Kim C, Vakulenko SB, Mobashery S & Shoichet BK (2005) Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM-lactamase. Biochemistry 44: 9330-9338.
114. Vakulenko S & Golemi D (2002) Mutant TEM β-lactamase producing resistance to ceftazidime, ampicillins, and β-lactamase inhibitors. Antimicrob Agents Ch 46: 646-653.
115. Vakulenko SB, Toth M, Taibi P, Mobashery S & Lerner SA (1995) Effects of Asp-179 mutations in TEM(Puc19) β-lactamase on susceptibility to β-lactams. Antimicrob Agents Ch 39: 1878-1880.
116. Vakulenko SB, Geryk B, Kotra LP, Mobashery S & Lerner SA (1998) Selection and characterization of β-lactam-β-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 β-lactamase gene. Antimicrob Agents Ch 42: 1542-1548.
117. Vakulenko SB, Taibi-Tronche P, Toth M, Massova I, Lerner SA & Mobashery S (1999) Effects on substrate profile by mutational substitutions at positions 164 and 179 of the class A TEMpUC19 β-lactamase from Escherichia coli. J Biol Chem 274: 23052-23060.
118. Venkatachalam KV, Huang WZ, Larocco M & Palzkill T (1994) Characterization of TEM-1 β-lactamase mutants from position 238 to position 241 with increased catalytic efficiency for ceftazidime. J Biol Chem 269: 23444-23450.
119. Wang XJ, Minasov G & Shoichet BK (2002a) Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol 320: 85-95.
120. Wang XJ, Minasov G & Shoichet BK (2002b) The structural bases of antibiotic resistance in the clinically derived mutant β-lactamases TEM-30, TEM-32, and TEM-34. J Biol Chem 277: 32149-32156.
121. Yang YJ, Rasmussen BA & Shlaes DM (1999) Class A β-lactamases: enzyme-inhibitor interactions and resistance. Pharmacol Therapeut 83: 141-151.
122. Yuan MF, Hall LMC, Savelkoul PHM, Vandenbroucke-Grauls CMJE & Livermore DM (2000) SHV-13, a novel extendedspectrum β-lactamase, in Klebsiella pneumoniae isolates from patients in an intensive care unit in Amsterdam. Antimicrob Agents Ch 44: 1081-1084.
123. Zaccolo M & Gherardi E (1999) The effect of high-frequency random mutagenesis on in vitro protein evolution: a study on TEM-1 β-lactamase. J Mol Biol 285: 775-783.
124. Zafaralla G, Manavathu EK, Lerner SA & Mobashery S (1992) Elucidation of the role of Arginine-244 in the turnover processes of class A β-lactamases. Biochemistry 31: 3847-3852.
125. Zarnayova M, Siebor E, Pechinot A, Duez JM, Bujdakova H, Labia R & Neuwirth C (2005) Survey of Enterobacteriaceae producing extended-spectrum β-lactamases in a Slovak hospital: dominance of SHV-2a and characterization of TEM-132. Antimicrob Agents Ch 49: 3066-3069.